Drug intelligence / Profile preview

SANT-7

Development stage: Preclinical
Modality: Peptides
Administration: In Vitro, Ex Vivo, Preclinical Models

Overview

SANT-7 is a synthetic peptide derivative that functions as a highly selective antagonist of the interleukin-6 receptor (IL-6R). By binding to the IL-6 receptor and blocking its interaction with interleukin-6 (IL-6), SANT-7 inhibits downstream IL-6-mediated signal transduction pathways. IL-6 is a cytokine involved in inflammatory responses, immune regulation, and tumor growth; thus, SANT-7 has been investigated as a potential therapeutic agent in diseases with elevated IL-6 signaling, including certain cancers and inflammatory diseases. The peptide was designed based on modifications of human IL-6 to selectively block receptor activation without intrinsic agonist activity.

Other names: SANT-7SANT7SANT 7

Targets

IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on SANT-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SANT-7.

Explore the full profile